The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Official Title: Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care
Study ID: NCT04486820
Brief Summary: Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.
Detailed Description: Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival.
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU de Saint-Etienne, Saint-Étienne, , France
Name: Georgia KARPATHIOU, MD
Affiliation: CHU SAINT-ETIENNE
Role: PRINCIPAL_INVESTIGATOR